Biotech | January 22, 2022
Lannett receives USFDA safety review for biosimilar insulin glargine
Go-ahead for pivotal clinical trial which is expected to commence by March
Go-ahead for pivotal clinical trial which is expected to commence by March
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
Subscribe To Our Newsletter & Stay Updated
